Loading...

The annual Enforcement, Litigation, and Compliance Conference brings together industry, regulators, attorneys, litigators, academics, and consultants to discuss trends and issues in enforcement and compliance, the latest developments in both civil and criminal litigation, and recent cases and settlements. This conference offers an opportunity to hear from and interact with top officials from FDA, DOJ, FTC, and other government agencies. 

Attendees will:

  • Explore the latest trends behind enforcement actions in food, drugs, biologics, medical devices, and tobacco
  • Gain practical tips and best practices for responding to enforcement action by FDA or other government agencies
  • Learn how to comply with new and upcoming FDA rules and regulations
  • Hear directly from FDA’s Center Compliance Directors on top issues, priorities, and goals for 2019

Register by October 18 and SAVE

Industry & Firms

$1099
  • +$400 for non-members
  • +$100 after 10/18/2018
  • +$100 after 11/15/2018

Non-Profit

$799
  • +$100 for non-members
  • +$100 after 10/18/2018
  • +$100 after 11/15/2018

Government

$799
  • +$100 for non-members
  • +$100 after 10/18/2018
  • +$100 after 11/15/2018

Academic

$799
  • +$100 for non-members
  • +$100 after 10/18/2018
  • +$100 after 11/15/2018

Student

$99
  • student registration
  • full-time students only
  • transcripts required
Register Now

To ensure that FDLI is able to provide you with a seat, materials, and meals, please register for programs at least 48 hours in advance. While onsite registration is available on a “space-available” basis; late registrants are not guaranteed materials or meals.

You can transfer your registration to another person at your organization for no cost by notifying us of the change. If you notify FDLI in writing at least five business days prior to the meeting, you can cancel your registration for a full refund (less a $75 fee). Refunds will be applied against the original form of payment.  

Our event policies are listed here. If you should have any further questions, please contact us at [email protected] or 800-956-6293.

Call for Proposals

FDLI and the Conference Planning Committee thanks those who participated in the Call for Proposals this summer. The input received from industry stakeholders helps us plan a timely program. If you submitted a proposal, you will be notified of the status of your proposal in September.

Premier Sponsor

Diamond Sponsor

Gold Sponsor

Silver Sponsor

Silver Sponsor

Silver Sponsor

 

 

Silver Sponsor

Silver Sponsor

Bronze Sponsor

Exhibitor

Last Year’s Agenda

A preliminary agenda will be announced in September. If you would like to be notified, please let us know.

Wednesday, December 6

8:00–8:45 AM                
Registration and Continental Breakfast

8:45–8:50 AM
Welcome and Opening Remarks
Amy Comstock Rick, President & CEO, Food and Drug Law Institute

8:50–9:20 AM                 
Keynote Address
Rebecca K. Wood, Chief Counsel, FDA

9:20–10:20 AM              
Compliance Central with FDA Center Compliance Directors: Part I
This two-part session will address FDA’s top compliance issues, enforcement priorities, and goals for 2018. Hear directly from each FDA Center Compliance Director, learn how industry should focus their compliance efforts, and what really happens when you don’t follow FDA regulations.

Donald Ashley, Director, Office of Compliance, Center for Drug Evaluation and Research, FDA
Sean Boyd, Deputy Director for Regulatory Affairs, Office of Compliance, Center for Devices and Radiological Health, FDA
Alonza Cruse, Director, Office of Pharmaceutical Quality Operations, ORA, FDA
Mary Malarkey, Director, Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research, FDA

Moderated by Cathy Burgess, Partner, Alston & Bird LLP and Chair, Enforcement, Litigation, and Compliance Conference

10:20–10:40 AM            
Coffee and Networking Break                                            

10:40–11:40 AM            
Compliance Central with FDA Center Compliance Directors: Part II

Daniel McChesney, Director, Office of Surveillance and Compliance, Center for Veterinary Medicine, FDA
William Correll, Director, Office of Compliance, Center for Food Safety and Nutrition, FDA
Ann Simoneau, Director, Office of Compliance and Enforcement, Center for Tobacco Products, FDA
Jennifer Thomas, Acting Director, Office of Enforcement and Import Operations, ORA, FDA

Moderated by ­­­Miriam Guggenheim, Partner, Covington & Burling LLP and Member, FDLI Board of Directors

11:40–12:30 PM            
Concurrent Breakout Sessions: How FDA’s Program Alignment Affects Your Industry
Why is the Program Alignment good for industry, and what are the challenges? What will be the impact on inspections, both domestic and foreign? During these breakout sessions, you will learn about the implications of FDA’s recent Program Alignment. Speakers will discuss what the new offices are, how program alignment will affect changes on the ground, and whether there have been any gaps or unintended consequences.

  1. Medical Products
    Alonza Cruse, Director, Office of Pharmaceutical Quality Operations, ORA, FDA
    Ginette Michaud, Director, Office of Biological Products Operations, ORA, FDA
    Moderated by Deborah M. Autor, SVP/Head of Strategic Global Quality & Regulatory Policy, Mylan Pharmaceuticals, Inc.
     
  2. Foods and Dietary Supplements
    Rend Al-Mondhiry,
    Associate General Counsel, Council for Responsible Nutrition
    Jennifer Thomas, Acting Director, Office of Enforcement and Import Operations, ORA, FDA
     
  3. Tobacco
    James Solyst, Vice President, Federal Regulatory Affairs, Swedish Match North America
    Jeffrey Weiss, General Counsel and EVP of Gov. Affairs, NJOY, Inc
    Moderated by Stacy L. Ehrlich, Partner, Kleinfeld, Kaplan & Becker, LLP and Member, FDLI Board of Directors

12:30–1:45 PM              
Networking Luncheon

1:45–2:45 PM                 
Concurrent Breakout Sessions in Your Industry

  1. Drug/Device: BIMO
    Each year, FDA publishes its BioResearch Monitoring (BIMO) inspection metrics that cover all the medical product centers at FDA. Violations included failure to have or follow investigational plans or continuing reviews, deviation from protocol, and inadequate records. These types of violations can easily be avoided with a strong Human Research Protection Program (HRPP). A good HRPP must be designed to support all those involved in the research endeavor through proper staffing and procedures, training and education, and monitoring and oversight. We will explore the regulatory requirements generally, what the common regulatory pitfalls are in this space, and how to design and manage an HRPP to avoid a problematic BIMO inspection. 
    David Burrow, Acting Director, Office of Study Integrity and Surveillance, CDER, FDA
    Chrissy J. Cochran, Director, Office of Bioresearch Monitoring Operations, ORA, FDA
    Heidi F. Gertner, Partner, Hogan Lovells US LLP
     
  2. FSMA Enforcement: The First Year
    Now that the first compliance dates for FSMA regulations have passed, the focus has shifted from preparation to implementation. What should you expect, and how can you prepare? What are both companies and inspectors seeing thus far? This session will feature first-hand accounts from attorneys on the FSMA “front lines,” and will include lessons learned so far from FDA enforcement.
    Steve Armstrong, Independent Consultant, EAS Consulting Group, LLC and Member, FDLI Board of Directors
    Mark C. Levy, Member, Eckert Seamans Cherin & Mellott, LLC
    Scott MacIntire, Director, Division of Enforcement, ORA, FD
     
  3. Tobacco: ENDS
    How FDA is enforcing against current active regulatory requirements (such as age restrictions) for websites, online marketplaces, and social media platforms? During this session, we will delve into FDA’s current enforcement and strategy around this area and understand how other companies within the space are combating these types of sales.
    Owen Chaput, Associate, Keller and Heckman LLP
    Patricia I. Kovacevic, General Counsel and Chief Compliance Officer, Nicopure Labs LLC
    Moderated by Bryan M. Haynes, Partner, Troutman Sanders LLP

 2:45–3:00 PM                 
Coffee and Networking Break   

 3:00–3:55 PM                 
Concurrent Breakout Sessions

  1. Drugs: Quality Systems Approach to Data Integrity
    This panel will delve into data integrity issues, including how to address data integrity problems and what the agency expects. Speakers will also analyze FDA’s “new” data integrity warning letter language and the expectations it creates for manufacturers, including how to respond.
    Bob Buhlmann, Director, Corporate Quality Assurance, Amgen, Inc.
    Jamie Colgin, Principal Consultant, Validant
    Moderated by Jack Garvey, Founder and CEO, Compliance Architects LLC 
     
  2. Medical Devices: Do I need to Open a CAPA?
    There is widespread disagreement in industry about when to open a Corrective and Preventive Action (CAPA). When is it appropriate to open a CAPA, and what are the implications of doing so, or choosing not to? What are agency expectations – should everything go into a CAPA? If not, how are non-CAPA activities managed, and where are they documented? What will FDA expect to see during an inspection? What role have CAPAs played in medical device litigation?
    Adrienne Franco Busby, Partner, Faegre Baker Daniels LLP
    Anne Miller, Principal Regulatory Counsel, Medtronic
    Marta L. Villarraga, Principal, Exponent, Inc.
    Moderated by Dennis Gucciardo, Senior Associate, Hogan Lovells US LLP
     
  3. FDA Regulation, Competitor Actions, and Private Litigation:
    In the food industry, labels and label claims have garnered enforcement actions from FDA, other government agencies, competitors, and private litigants based. A company could find itself in the midst of all of the above, based on a single claim on one product. What are key techniques to avoid prevent or minimize risk of an enforcement action by a government agency – FDA or otherwise – and subsequent action by a private actor? What can other industries learn from what has happened in the food industry?
    Leslie Krasny, Partner, Keller and Heckman LLP
    Deborah Livornese, Of Counsel, Arnall Golden Gregory LLP
    Yvonne M. McKenzie, Partner, Pepper Hamilton LLP

4:00–5:00 PM                 
Enforcement Throughout the Supply Chain
As companies continue to shift manufacturing operations and procurement overseas, knowing your supply chain and having comprehensive quality agreements becomes increasingly important. In addition, there are substantive differences between foreign inspections and domestic inspections, in terms of notice and agency responsibility, and more subtle differences, in terms of cultural differences, language barriers, and actions that FDA has viewed as delaying, denying, limiting, or refusing an inspection, which can lead to enforcement actions. This session will discuss how to succeed in foreign inspections, what your responsibilities are, and ensuring your supply chain is secure.

Frederick (Rick) Ball, Partner, Duane Morris LLP and Member, FDLI Board of Directors
Paula R. Katz, Director, Manufacturing Quality Guidance and Policy Staff, CDER, FDA
Anne K. Walsh, Director, Hyman, Phelps & McNamara, PC

Moderated by Howard R. Sklamberg, Partner, Akin Gump Strauss Hauer & Feld LLP

5:00–7:00 PM                 
FDLI 2017 Annual Holiday Reception

Thursday, December 7

8:30–8:55 AM                
Registration and Continental Breakfast

8:55–9:00 AM                 
FDLI Welcome and Remarks

Laura Brown, Director, Educational Programs, FDLI

9:00–9:45 AM                
Keynote Address
Ethan Davis, Deputy Assistant Attorney General, Consumer Protection Branch, US Department of Justice

9:45–10:45 AM              
Recent Trends in Criminal Enforcement
This session will provide an overview of recent criminal cases, and current priorities for OCI and DOJ with respect to criminal prosecutions.  In addition, panelists will discuss how to avoid criminal prosecution, and best practices for responding if you or your firm is the target of a criminal investigation.

Jill Furman, Deputy Director, Consumer Protection Branch, US Department of Justice
George M. Karavetsos, Partner, DLA Piper LLP
Peter J. Leininger, Counsel, King & Spalding LLP
Thomas South, Special Agent in Charge of Investigative Operations, Office of Criminal Investigations, FDA

Moderated by William F. Gould, Partner, Holland & Knight LLP

10:45–11:00 AM            
Coffee and Networking Break

11:00–12:00 PM            
Management Oversight and Control: How to Ensure Compliance and Limit Liability
FDA expects senior management to exercise appropriate oversight and control of manufacturing operations to ensure product quality and public safety.  Panelist will discuss management responsibility and communications related to establishment inspections, recalls, warning letters and government enforcement.  The panel will also discuss how communications on these topics have the potential to trigger shareholder derivative suits or product liability, and how to mitigate these risks. 

Jennifer Bragg, Partner, Skadden, Arps, Slate, Meagher & Flom LLP and Member, FDLI Board of Directors
Ricki A. Chase, Director, Compliance Practice, Lachman Consultants John H. Fuson, Partner, Crowell & Moring LLP

Moderated by Geoffrey M. Levitt, Senior Vice President & Associate General Counsel, Pfizer, Inc.

12:05–1:00 PM              
Concurrent Breakout Sessions

  1. ORA and CDER: A New Concept of Operations (ConOps)
    The Center for Drug Evaluation and Research (CDER) and the Office of Regulatory Affairs (ORA) have entered into an unprecedented concept of operations (ConOps) agreement to integrate facility evaluations and inspections for human drugs. The agreement, Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations, outlines the responsibilities and the workflow for Pre-Approval, Post-Approval, Surveillance, and For-Cause Inspections at domestic and international facilities. This panel will discuss the improvements in communications and processes between ORA and CDER, and consider the impacts on industry.
    Alonza Cruse, Director, Office of Pharmaceutical Quality Operations, ORA, FDA
    Allison Fulton, Partner, Sidley Austin LLP
    Paula R. Katz, Director, Manufacturing Quality Guidance and Policy Staff, CDER, FDA
    Moderated by John Manthei, Partner, Latham & Watkins LLP
     
  2. Medical Devices: Cybersecurity, IoT, and FDA
    As medical devices become more integrated into an increasingly digital healthcare infrastructure, they are vulnerable to being exposed to privacy and security threats that could have broad implications for patient health, the manufacturers reputation, lawsuits, and fines. This session will discuss the infrastructure that has been put in place to protect the medical device ecosystem against cyber threats and risks, and what different segments of industry are proactively doing to keep patients and communities safe.
    David J. Bloch, Principal Legal Counsel, Corporate Legal Regulatory, Medtronic
    Neil F. O’Flaherty, Partner, Baker & McKenzie
    Moderated by Sonali Gunawardhana, Of Counsel, Wiley Rein LLP
     
  3. First Amendment Issues in Advertising and Product Packaging
    This session will address First Amendment concerns with regard to advertising and promoting a product, and will be geared toward food and tobacco-related issues, such as product packaging.
    August T. Horvath, Partner, Kelley Drye & Warren LLP

1:00–2:00 PM                 
Luncheon Address: Fifth Annual Eric M. Blumberg Memorial Lecture
Ann Wion, former Deputy Chief Counsel for Program Review, Office of the Chief Counsel, FDA

2:00 PM                           
Conference Adjournment

2018 Planning Committee

Deborah Autor, Mylan
Jack Garvey, Compliance Architects LLC
George Karavetsos, DLA Piper
Mark Mansour, Foley Hoag LLP
Matthew Newcomer, Post & Schell PC
Cynthia Schnedar, Greenleaf Health LLC
Howard Sklamberg, Akin Gump
Kim Trautman, NSF Health Sciences
Anne Walsh, Hyman Phelps & McNamara PC
Jessica Zeller, FDA/ORA

Continuing Legal Education

FDLI applies for CLE credits in Ohio, Pennsylvania, and Virginia. These CLE approvals may also be honored by other states; please check with your bar association for guidance. The CLE credits will be posted as they are granted and you can request to be notified when approval is received.

Conference Location

JW Marriott
1331 Pennsylvania Ave NW
Washington, DC 20004

2018-08-14T13:39:28+00:00